gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Complement component 5a receptor 1

C5a, Complement C5, C5aR
likely component of the classical pathway of the complement cascade; may be involved with tissue injury associated with ischemia or sepsis; may be a component of the membrane attack complex [RGD, Feb 2006] (from NCBI)
Top mentioned proteins: CAN, C3aR, V1a, HAD, C5L2
Papers using C5a antibodies
Imagable 4T1 model for the study of late stage breast cancer
Yoon Park Jung Han et al., In Breast Cancer Research : BCR, 2007
... myeloid cells (TREM)-1 from R and D Systems (Minneapolis, MN, USA); ELISA kits for complement fragment 5a (C5a) and interleukin (IL)-16 from USCN Life Science and Technology Company (Missouri ...
Papers on C5a
Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation.
Tiede et al., Hannover, Germany. In Xenotransplantation, Feb 2016
Specific inhibition of complement C5 by eculizumab prevented endothelial cell activation, but also coagulation and platelet activation without compromising thrombin generation capacity of human blood or normal platelet function.
The role of complement system in adipose tissue-related inflammation.
Rus et al., Baltimore, United States. In Immunol Res, Feb 2016
The C3a receptor and C5aR are involved in the development of adipocytes' insulin resistance through macrophage infiltration and the activation of adipose tissue.
Increased Susceptibility of Humanized NSG Mice to Panton-Valentine Leukocidin and Staphylococcus aureus Skin Infection.
Liu et al., Los Angeles, United States. In Plos Pathog, Nov 2015
PMX53, a human C5aR inhibitor, blocked PVL-induced cellular cytotoxicity in vitro and reduced the size difference of lesions induced by the PVL+ and PVL- S. aureus, but PMX53 also reduced recruitment of neutrophils and exacerbated the infection.
Complement involvement in kidney diseases: From physiopathology to therapeutical targeting.
Bertoni et al., Florence, Italy. In World J Nephrol, Jun 2015
Even if only the anti C5 monoclonal antibody is on the market, many targets as C1, C3, C5a and C5aR are the object of national or international trials.
Improvement of prognostic performance in severely injured patients by integrated clinico-transcriptomics: a translational approach.
Wanner et al., Zürich, Switzerland. In Crit Care, 2014
RESULTS: Leukocytes, thrombocytes and the expression of sphingosine kinase-1 (SPHK1), complement C5, and haptoglobin (HP) have been identified as markers with the best performance.
C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.
Gallay et al., United States. In Antimicrob Agents Chemother, 2014
Here, we evaluated the safety and microbicidal efficacy of a short amphipathic peptide, C5A, in a rhesus macaque model.
Role of Complement on Broken Surfaces After Trauma.
Brenner et al., Ulm, Germany. In Adv Exp Med Biol, 2014
In addition, key complement components and the corresponding receptors (such as C3aR, C5aR) have been detected on "exposed surfaces" of the damaged regions.
The effect of nuclear factor of activated T-cells (NFAT) in kidney I/R mediated by C5a/C5aR.
Liu et al., Wuhan, China. In Int J Clin Exp Med, 2014
To investigate the relationship between NFAT and C5a/C5aR in C5a/C5aR-mediated kidney Ischemia/reperfusion (I/R) injury, the rats' NRK-52E cell line was used in this study and was distributed into 4 groups, I: the normal control (NC), II: the ischemia/reperfusion (I/R) injury cell model (MG), III: the ischemia/reperfusion (I/R) injury cell model treated with C5a (50 nmol/l) (MG + C5a), IV: the ischemia/reperfusion (I/R) injury cell model treated with C5aR antagonist (2.5 μmol/l) (MG + anti-C5aR).
Attenuating the Systemic Inflammatory Response to Adult Cardiopulmonary Bypass: A Critical Review of the Evidence Base.
Hammon et al., In J Extra Corpor Technol, 2014
Interventions at level A evidence included off-pump surgery, minimized circuits, biocompatible circuit coatings, leukocyte filtration, complement C5 inhibition, preoperative aspirin, and corticosteroid prophylaxis.
Acute lung injury and the role of histones.
Grailer et al., Ann Arbor, United States. In Transl Respir Med, 2013
We have studied experimental acute lung injury (ALI) in mice following airway deposition of bacterial lipopolysaccharide (LPS) or the recombinant mouse complement anaphylatoxin, C5a.
Absence of signaling into CD4⁺ cells via C3aR and C5aR enables autoinductive TGF-β1 signaling and induction of Foxp3⁺ regulatory T cells.
Medof et al., Cleveland, United States. In Nat Immunol, 2013
Signaling through the G protein-coupled receptors for the complement fragments C3a and C5a (C3aR and C5aR, respectively) by dendritic cells and CD4(+) cells provides costimulatory and survival signals to effector T cells.
Roles of promoter and 3' untranslated motifs in expression of the human C5a receptor.
van den Berg et al., Cardiff, United Kingdom. In Mol Immunol, 2012
Analysis of the 3'UTR of the C5aR mRNA showed that it contained two AU-rich elements (AREs), however site directed mutagenesis showed that these had no effect on basal expression.
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1.
Köhl et al., Lübeck, Germany. In Nat Med, 2012
Here we demonstrate that IgG1 immune complexes (ICs), the inhibitory IgG receptor FcγRIIB and the C-type lectin–like receptor dectin-1 suppress C5a receptor (C5aR) functions.
Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway.
Stadnyk et al., Halifax, Canada. In Am J Physiol Cell Physiol, 2012
Intestinal epithelial cells express C5aR apically and directly respond to C5a through the ERK signaling pathway.
Complement C5A regulates prolabor mediators in human placenta.
Permezel et al., Melbourne, Australia. In Biol Reprod, 2012
Complement C5a upregulates prolabor mediators in human gestational tissues via CD88-mediated NFKB activation.
Complement activation product C5a is a selective suppressor of TLR4-induced, but not TLR3-induced, production of IL-27(p28) from macrophages.
Ward et al., Ann Arbor, United States. In J Immunol, 2012
C5a robustly suppresses IL-27(p28) gene expression and release in peritoneal macrophages.
C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity.
Song et al., Philadelphia, United States. In J Immunol, 2012
a surprising role for the 3'-untranslated region of C5aR mRNA in regulating C5aR protein targeting to the plasma membrane.
Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma.
Wills-Karp et al., Cincinnati, United States. In Nat Immunol, 2010
Mechanistically, we demonstrate that IL-17A and AHR were regulated by allergen-driven production of anaphylatoxins, as mouse strains deficient in complement factor 5 (C5) or the complement receptor C5aR mounted robust IL-17A responses, whereas mice deficient in C3aR had fewer IL-17-producing helper T cells (T(H)17 cells) and less AHR after allergen challenge.
Eculizumab for paroxysmal nocturnal haemoglobinuria.
Parker, Salt Lake City, United States. In Lancet, 2009
Eculizumab is a humanised monoclonal antibody that binds and prevents activation of complement C5 and the subsequent formation of the cytolytic membrane attack complex of complement.
Functional roles for C5a receptors in sepsis.
Ward et al., Ann Arbor, United States. In Nat Med, 2008
C5ar and C5l2 contribute synergistically to the harmful consequences in sepsis.
share on facebooktweetadd +1mail to friends